Arrhythmogenic right ventricular dysplasia/cardiomyopathy was first reported as the partial replacement of the right ventricular myocardium by fat or fibrous tissue. In 1965, researchers described the ...

Background Regular intensive physical activity is associated with non-pathological changes in cardiac morphology. Differential diagnosis with arrhythmogenic right ventricular cardiomyopathy (ARVC) ...

The first-line therapy for arrhythmogenic right ventricular cardiomyopathy (ARVC) is considered to be β-blockers, which are generally well tolerated. However, findings from the Multidisciplinary ...

may lead to a proarrhythmic state resembling right (or less often) left ventricular cardiomyopathy. This can develop even in the absence of underlying demonstrable genetic abnormalities, probably just ...

Abbreviations: ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; VT, ventricular tachycardia. Author's Contributions: P Petrakopoulou and M Greif contributed equally to the ...

Abbreviations: ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; VT, ventricular tachycardia. Author's Contributions: P Petrakopoulou and M Greif contributed equally to the ...

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...

The classic ECG findings in arrhythmogenic right ventricular dysplasia are inverted T waves in the right precordial leads (V1-V3) with an epsilon wave after the QRS in lead V1, representing early ...

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics Inc (NASDAQ:TNYA), with a price target of $18.00. This aligns with the strong overall analyst consensus, as ...

This does not occur in restrictive cardiomyopathy. With inspiration, intrathoracic pressure decreases and the right ventricle fills. This causes the right ventricular pressure to increase ...